Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tylenol and COX-2 inhibitors

This article was originally published in The Tan Sheet

Executive Summary

Two McNeil TV ads that broke March 7 in the "Tylenol House Call" series discuss the new prescription arthritis pain reliever celecoxib (Searle/Pfizer's Celebrex) ("The Tan Sheet" Jan. 11, p. 8). The ads urge consumers with "common arthritis" to "talk to your doctor. For most people with common arthritis pain, the first choice of arthritis experts is the medicine in Tylenol," one ad states. Furthermore, the ad notes: "This new COX-2 prescription has not been shown to relieve arthritis pain better than Tylenol. And no other type of pain reliever, prescription or over-the-counter, is gentler on your stomach than Tylenol." The second ad urges consumers curious about the COX-2 to ask their doctors "how does it compare to other products?" to "ask your doctor about its safety profile" and to "finally, check the cost." A month's worth of Celebrex can cost "almost $100 a month," the ad states

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089542

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel